John Mendelsohn: A visionary scientist, oncologist and leader

Dr. John Mendelsohn is credited for the concept of targeting the epidermal growth factor receptor (EGFR), providing the first evidence of anticancer activity of antagonist anti-EGFR mAb, and developing the Erbitux (Cetuximab) drug for cancer patients. During his professional journey, Dr. Mendelsohn...

Full description

Bibliographic Details
Main Authors: Kumar, Rakesh, Murad, Ferid, Bogler, Oliver, O'Malley, Bert W., Hortobagyi, Gabriel N.
Format: Online Article Text
Language:English
Published: Impact Journals LLC 2019
Subjects:
Commentary
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6872667/
https://www.ncbi.nlm.nih.gov/pubmed/31798764
http://dx.doi.org/10.18632/genesandcancer.195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6872667/
https://www.ncbi.nlm.nih.gov/pubmed/31798764
http://dx.doi.org/10.18632/genesandcancer.195

Similar Items